-
The FDA has approved an extended-release form of zolpidem. The drug delivery system consists of a coated 2-layer tablet, one releases the drug immediately and the other provides a slower release. Zolpidem extended-release (zolpidem ER) is marketed by Sanofi-Synthelabo as Ambien CR.
-
The FDA has approved a new single booster vaccine against pertussis, diphtheria, and tetanus for adolescents and adults. Aventis Pasteur Limited will market the new vaccine as Adacel. In contrast to the combination vaccine for use in infants and children, Adacel contains diphtheria toxoid and one of the pertussis components (detoxified pertussis toxoid) in reduced quantities. The new vaccine is similar to Boostrix® marketed by GlaxoSmithKline which was approved only for adolescents ages 10-18 years
-
For healthy patients without heart disease, starting levothyroxine at full dose is safe and shortens the time to a euthyroid state.
-
Invasive coronary angiography as of this time remains the gold standard of coronary arterial imaging and, even though the risks of this procedure are quite small (total complication rate of 1.8% and mortality rate of 0.1%), catheterization does expose patients to potential discomfort and, therefore, its use is usually restricted by relatively stringent clinical indications and guidelines.
-
Patients who have had a transient ischemic attack have not only a high short-term chance of ischemic stroke but also a long-term risk of vascular events over 10 years or more.
-
A 3.3-fold increase in acute urinary retention was found in new male users of nonsteroidal anti-inflammatory drugs (NSAIDs) compared to non-users in a large primary care database from the Netherlands. The risk for all male NSAID users was 2.3-fold greater.
-
Modafinil for Excessive Sleepiness Associated with Shift-Work Sleep Disorder; Acupuncture in Patients with OAK; Risk of Prostate Cancer-Specific Mortality Following Biochemical Recurrence after Radical Prostatectomy
-
-
-
